Anti-amyloid Alzheimer's drugs show no clinically meaningful effect

medicalxpress - Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new review in the Cochrane Database of Systematic Reviews has found.

AI Summary: A major review concludes anti-amyloid Alzheimer’s medications show no clinically meaningful effect on patients’ cognition or daily function, prompting renewed debate about drug approvals, prescribing and research priorities. The analysis calls for careful reassessment of treatment value, clearer communication to patients and tighter scrutiny of future trials.

• Anti-amyloid drugs fall short: little benefit, safety risks (5)
• New biomarkers and imaging reshape Alzheimer’s diagnosis timing (3)
• Social and care issues: loneliness, memory and treatment decisions (2)
• All Other Stories

Anti-amyloid drugs fall short: little benefit, safety risks

New biomarkers and imaging reshape Alzheimer’s diagnosis timing

Social and care issues: loneliness, memory and treatment decisions

All Other Stories